Research programme: neuropathic pain therapeutics - Sangamo Therapeutics
Alternative Names: Nav-1.7Latest Information Update: 18 Mar 2024
At a glance
- Originator Sangamo Therapeutics
- Class Analgesics; Gene therapies; Zinc finger DNA binding proteins
- Mechanism of Action NAV1.7 voltage gated sodium channel expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 13 Mar 2024 Sangamo Therapeutics plans to submit IND application for neuropathic pain therapeutics in Neuropathic pain the fourth quarter of 2024
- 13 Mar 2024 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by Sangamo Therapeutics
- 23 May 2023 Nav 1.7 is available for licensing as of 23 May 2023. https://www.sangamo.com/collaborations (Sangamo therapeutics website; May 2023)